Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Pro-inflammatory diets up oral cancer risk

05 Jul 2020
10 cancer avoidance tips for your patients

Keeping a more pro-inflammatory diet may increase the risk of developing oral cancer, a recent China study has shown.

Researchers conducted a case-control study on 295 oral cancer patients (mean age, 57.80±16.04 years; 62.71 percent male) in whom diet information was collected using a food frequency questionnaire (FFQ). Intake was evaluated through the Energy adjusted Dietary Inflammatory Index (E-DII). A parallel group of 425 controls (mean age, 59.22±12.62 years; 69.41 percent male) was also included.

Compared to controls, cancer cases had a higher level of tobacco and alcohol consumption, as well as an elevated median E-DII score (6.94 vs 5.37).

Unconditional logistic regression models found a significant link between E-DII and oral cancer. In the fully adjusted model, each unit increase in E-DII correlated with a 3-percent spike in the likelihood of developing oral cancer (odds ratio [OR], 1.03, 95 percent confidence interval [CI], 1.00–1.06).

When E-DII was taken as a discrete variable and participants were grouped into quartiles of scores, the fully adjusted model found that keeping the most pro-inflammatory diet more than doubled the risk of oral cancer (OR, 2.57, 95 percent CI, 1.54–2.42). Those in the third quartile of E-DII scores also had almost twice the risk of oral cancer than those in the first quartile (OR, 1.92, 95 percent CI, 1.12–3.31).

Stratified analysis showed that the interaction between E-DII and oral cancer was stronger among males, those >60 years of age, never-smokers, alcohol drinkers, tea drinkers, and those with poor oral hygiene.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.